Erasca, INC Schedule 13G passive stakes

RTW Investments, LP and Roderick Wong have reported beneficial ownership of 16,157,175 shares, representing 5.2% of Erasca, Inc.'s common stock as of March 31, 2026.

Suvretta Capital Management and Aaron Cowen have filed an amendment to their Schedule 13G regarding their holdings in Erasca, Inc.

T. Rowe Price Investment Management, Inc. has disclosed a 5.7% beneficial ownership stake in ERASCA INC, holding over 16 million shares of common stock.

Paradigm BioCapital Advisors LP and related entities have reported a 5.3% beneficial ownership stake in Erasca, Inc.'s common stock as of January 7, 2026.

Logos Global Management LP and its affiliates have reduced their beneficial ownership in Erasca, Inc. to 4.8% of the common stock.

Logos Global Management LP, along with its general partner and control person, reported a 5.3% passive beneficial ownership stake in Erasca, Inc. common stock.

T. Rowe Price Investment Management, Inc. reported an increased beneficial ownership of 7.2% in ERASCA INC's common stock as of June 30, 2025.

Frazier Life Sciences funds update their beneficial ownership filing for Erasca, Inc., clarifying control over significant equity holdings.

Suvretta Capital Management, LLC and affiliates report a 5.1% beneficial ownership stake in Erasca, Inc. common stock.

Frazier Life Sciences Public Fund and affiliated entities, along with key principals, have filed an amended Schedule 13G/A, disclosing a collective beneficial ownership of 8.0% in Erasca, Inc.'s common stock as of March 31, 2025.

Suvretta Capital Management, LLC, along with Averill Master Fund, Ltd. and Aaron Cowen, has filed an amended Schedule 13G indicating their beneficial ownership in Erasca, Inc. has fallen to 4.4% as of December 31, 2024.

Novartis Pharma AG and its parent company Novartis AG have filed an amended Schedule 13G, disclosing a beneficial ownership of 4.4% in Erasca, Inc., totaling 12,307,692 shares of common stock as of December 31, 2024.